Acadia Selected to Participate in Seelos Therapeutics Study
Acadia is honored to have been selected by Seelos Therapeutics to participate in a registration-directed study aimed at determining whether intranasal racemic ketamine can reduce symptoms of suicidal ideation in individuals who are suffering from depression.
